Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical (LFCR) Non-Current Deffered Revenue: 2012-2024

Historic Non-Current Deffered Revenue for Lifecore Biomedical (LFCR) over the last 3 years, with Nov 2024 value amounting to $4.9 million.

  • Lifecore Biomedical's Non-Current Deffered Revenue rose 1420.25% to $4.9 million in Q4 2024 from the same period last year, while for Nov 2024 it was $4.9 million, marking a year-over-year increase of 1420.25%. This contributed to the annual value of $4.7 million for FY2024, which is 59.97% up from last year.
  • According to the latest figures from Q4 2024, Lifecore Biomedical's Non-Current Deffered Revenue is $4.9 million, which was up 1.86% from $4.8 million recorded in Q3 2024.
  • In the past 5 years, Lifecore Biomedical's Non-Current Deffered Revenue ranged from a high of $4.9 million in Q4 2024 and a low of $321,000 during Q4 2023.
  • For the 2-year period, Lifecore Biomedical's Non-Current Deffered Revenue averaged around $3.2 million, with its median value being $3.8 million (2023).
  • Data for Lifecore Biomedical's Non-Current Deffered Revenue shows a peak YoY spiked of 1,420.25% (in 2024) over the last 5 years.
  • Lifecore Biomedical's Non-Current Deffered Revenue (Quarterly) stood at $321,000 in 2023, then skyrocketed by 1,420.25% to $4.9 million in 2024.
  • Its Non-Current Deffered Revenue was $4.9 million in Q4 2024, compared to $4.8 million in Q3 2024 and $4.7 million in Q2 2024.